SCHEMBL2552183

SCHEMBL2552183

O=[N+]([O-])c1ccc(Sc2ccnc(Cl)c2)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 9/20 0.47
PDE7B Q9NP56 3/20 0.47
PDE4B Q07343 2/20 0.47
PDE4D Q08499 2/20 0.47
POLB P06746 1/20 0.44
IDO1 P14902 1/20 0.44
TDP1 Q9NUW8 5/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPT P10636 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
PKM P14618 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2552028 0.77 NCF1 (0.38) PDE7AIDO1MEN1KMT2AALDH1A1
SCHEMBL11302681 0.77 TDP1 (0.59) PDE7APDE7BTDP1MEN1KMT2A
SCHEMBL190818 0.74 SIRT2 (0.44) MAPTMAPK1ALDH1A1SMN1; SMN2LMNA
SCHEMBL17008483 0.70 KMT2A (0.46) POLBTDP1MEN1KMT2AMAPT
SCHEMBL31086622 0.70 KMT2A (0.46) POLBTDP1MEN1KMT2AMAPT
SCHEMBL191204 0.70 HPGD (0.44) PDE7APDE7BPDE4BPDE4DTDP1
SCHEMBL7788656 0.68 TDP1 (0.80) PDE4DPOLBTDP1MEN1KMT2A
SCHEMBL27545079 0.68 TDP1 (0.55) TDP1MEN1KMT2AGAAALDH1A1
SCHEMBL191141 0.67 TRPA1 (0.47) IDO1TDP1MEN1KMT2AMAPT
SCHEMBL190418 0.66 PKM (0.49) POLBTDP1ALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2556068-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2019-01-23 EP disclosed
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 US disclosed
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 US disclosed
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 US disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 US disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 US disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 US disclosed
EP-2556068-A1 P38 MAP KINASE INHIBITORS Respivert Limited (GB) 2013-02-13 EP disclosed
WO-2011124930-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2011-10-13 WO disclosed
WO-2011124930-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040962-A1 P38 MAP Kinase Inhibitors MAPK15, MAPK1, MAP3K15 PDE7A 504/4885PDE7B 200/4885PDE4B 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.